Romel Wrenn, MD
Interventional Cardiology · Fairbanks, AKNPI 1255302717
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $16,882 of the $21,821 with a category attached, or 77.4%. 26 manufacturers reported payments, led by Siemens Medical Solutions USA, Inc. at 52.1% of the total. Reporting peaked in 2019 at $14,537 and has fallen 70.9% since, to $4,237 in 2025.
Across 151 payments — averaging $144.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Siemens Medical Solutions USA, Inc.$11K
- Abbott$3K
- Medtronic$2K
- GE HealthCare$2K
- E.r. Squibb & Sons, L.L.C.$1K
- AstraZeneca$276
- plus $2K from 20 others
What the payments were for
- Travel & lodging$16,88277%
- Food & beverage$4,93923%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Siemens Medical Solutions USA, Inc. | 14 | $11,375 |
| Abbott | 11 | $2,651 |
| Medtronic(2 entities) | 24 | $2,388 |
| GE HealthCare | 4 | $2,294 |
| E.r. Squibb & Sons, L.L.C. | 37 | $1,029 |
| AstraZeneca | 3 | $276 |
| Novartis | 10 | $270 |
| Boston Scientific | 3 | $266 |
| Amgen | 8 | $197 |
| Chiesi USA, Inc. | 4 | $193 |
| Pfizer | 7 | $154 |
| Akcea Therapeutics, Inc. | 2 | $124 |
| Merck | 5 | $113 |
| Shockwave Medical, Inc | 3 | $75 |
| ZOLL Respicardia, Inc. | 1 | $66 |
| Johnson & Johnson | 4 | $63 |
| Braemar Manufacturing, LLC | 1 | $54 |
| Anumana, Inc. | 1 | $46 |
| Bridgebio Pharma, Inc. | 1 | $41 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $32 |
| Boehringer Ingelheim | 1 | $32 |
| Lundbeck LLC | 1 | $22 |
| Philips North America LLC | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $14 |
| Baxter Healthcare | 1 | $14 |
| Bardy Diagnostics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Artis icono$10,652
- XIENCE SKYPOINT$2,205
- Micra$470
- Artis Q.zen$462
- FARXIGA$254
- ELIQUIS$234
- SelectSecure$148
- KENGREAL$143
- MitraClip$136
- CAMZYOS$125
- WATCHMAN Access System$118
- JOT DX$111
- TEGSEDI$101
How this compares
Too few interventional cardiology providers in Alaskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 226 | $342,163 |
| XareltoRivaroxaban | 46 | $69,562 |
| Repatha SureclickEvolocumab | 42 | $61,200 |
| EntrestoSacubitril/Valsartan | 42 | $57,208 |
| BrilintaTicagrelor | 29 | $34,367 |
| JardianceEmpagliflozin | 16 | $25,216 |
| MultaqDronedarone Hcl | 11 | $22,956 |
| Metoprolol Succinate | 271 | $5,505 |
| Rosuvastatin Calcium | 140 | $2,213 |
| Losartan Potassium | 166 | $1,989 |
| Atorvastatin Calcium | 160 | $1,933 |
| Carvedilol | 124 | $1,429 |
| Ezetimibe | 70 | $1,408 |
| Potassium Chloride | 55 | $1,353 |
| Labetalol Hcl | 28 | $1,245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $154 | $342,163226 claims |
| Johnson & JohnsonXarelto | $63 | $69,56246 claims |
| NovartisEntresto | $270 | $57,20842 claims |
| AstraZenecaBrilinta | $276 | $34,36729 claims |
| Boehringer IngelheimJardiance | $32 | $25,21616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional cardiology providers in Alaskaon file to place this against a meaningful peer group, so we don't.
Other interventional cardiology in Fairbanks
- Josiah BrownAnchorage$15K
- David LemonsPalmer$7K
- Ryan McDonoughPalmer$7K
- Jasleen TiwanaAnchorage$5K
- Carson WebbAnchorage$4K
- Thomas KramerAnchorage$2K
- Richard AnschuetzAnchorage$1K
- Blake CharltonAnchorage$1K
- Lee PiersonAnchorage$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.